Medicare Insurance Type and Broad Genomic Profiling in Metastatic Cancer - Scorecard - MDSpire

Medicare Insurance Type and Broad Genomic Profiling in Metastatic Cancer

  • By

  • Ryan D. Chow

  • John Rothen

  • Jessica B. Long

  • Pamela R. Soulos

  • Xiao Wang

  • Ronac Mamtani

  • Shuangge Ma

  • Natalia Kunst

  • Michaela A. Dinan

  • Cary P. Gross

  • May 27, 2026

  • 0 min

Share

Clinical Scorecard: Medicare Coverage and the Utilization of Comprehensive Genomic Profiling in Advanced Cancer Cases

At a Glance

CategoryDetail
Condition
Key MechanismsBroad genomic profiling (BGP) for metastatic cancer treatment as per national guidelines.
Target Population
Care Setting

Key Highlights

  • Medicare issued a national coverage determination for BGP testing in 2018.
  • BGP use remains underutilized despite increasing recommendations.

Guideline-Based Recommendations

Diagnosis

    Management

    • Implement BGP for patients with metastatic cancer as per national guidelines.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Medicare patients aged 66 years or older with metastatic cancer.

        BGP involves sequencing of 10 or more genes in a single day.

        Clinical Best Practices

          Related Resources & Content

          Original Source(s)

          Medicare Insurance Type and Broad Genomic Profiling in Metastatic Cancer

          • by Ryan D. Chow, John Rothen, Jessica B. Long, Pamela R. Soulos, Xiao Wang, Ronac Mamtani, Shuangge Ma, Natalia Kunst, Michaela A. Dinan, Cary P. Gross

          • May 27, 2026

          Related Content

          Recurrent pleuropulmonary blastoma type III initially misclassified as embryonal rhabdomyosarcoma on limited biopsy: a case report with pathogenic DICER1 variant

          Stimuli-responsive nanoplatforms for sonodynamic immunotherapy: opportunities and challenges in cancer treatment

          MRI perfusion in evaluating ovarian masses: diagnostic performance of wash out rate